The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes/weight-loss med tirzepatide is over. Tirzepatide includes blockbuster ...

After a second investigation, the FDA announced tirzepatide will no longer be on the agency’s drug shortage list. Dates were announced for distribution of compounded forms for the drugs to end.